Replimune Wins FDA Approval for Melanoma Drug After Two Rejections

Amazon just put weight-loss drugs in front of Medicare patients for fifty dollars a month — and it didn't negotiate a single rebate to do it.

Lilly cleared consensus on both lines, Insmed added thirty-three percent in a session, and a mega-merger both companies swear never happened still took a bite out of AstraZeneca. Busy Thursday. Let's get into it.

Welcome to The Pharma Closeout for Thursday, August 6th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Amazon's pharmacy unit said Thursday it will offer weight-loss drugs to eligible Medicare beneficiaries for fifty dollars a month, through the new federal Medicare Bridge Program. That's Reuters this morning. Everyone's going to fixate on the fifty dollars. The number that actually moves product is twenty-four hours — and I'll come back to that.

Start with the program, because it's what makes any of this possible. Washington launched it last month. It runs through the end of 2027. Eligible beneficiaries can get Novo's Wegovy — injection or pill — plus Lilly's four-dose Zepbound KwikPen and the Foundayo pill. Single-dose Zepbound vials and pens are excluded. So the coverage fight in Medicare obesity was already settled by the government. What nobody had solved was who does the paperwork.

That's the move. Amazon automates eligibility checks, prior authorization, billing — all of it. Patient loads insurance and Medicare details into the account, a clinician sends an electronic script, and Amazon starts the enrollment on the patient's behalf. Now the twenty-four hours: the company told Reuters most of its bridge patients got a prior authorization decision in under a day, against the seventy-two the program allows. Then home delivery or in-store pickup — same-day in more than three thousand one hundred cities and towns, expanding to nearly four and a half thousand by year-end.

Here's my issue with calling this pricing disruption. Fifty dollars is a beneficiary cost-share inside a federal program. It isn't a price Amazon negotiated with Lilly or Novo, and the net economics back to either manufacturer aren't public. "Amazon reprices obesity" runs a step ahead of anything we can actually see.

That's fair. The price isn't the disruption — the conversion is.

Then the honest read is Amazon didn't buy a discount. It bought the prior-authorization clock. The gap between a clinician writing the script and a patient holding the pen is where this category leaks, and it leaks hardest in the population carrying the most comorbidity. Compress seventy-two hours to under twenty-four and you convert scripts that were going to die in a queue. Channel share moves without a dollar of list price changing.

And Amazon owns both ends of the pipe. One Medical — the primary care business they bought, a hundred and ninety-nine dollars a year — is where the prescription gets written. The pharmacy is where it lands. There's nobody in the middle left to slow it down.

For anyone sitting in access, the detail I'd underline is what's in and what's out. The four-dose KwikPen is covered. Single-dose vials and pens aren't. That's a device-level carve-out, and it quietly steers titration and refill cadence toward the multi-dose presentation — that's a manufacturing and forecasting decision, not a formulary one. And with both oral options inside the program, any persistence data coming out of this cohort is channel-confounded from day one. Be very careful what you benchmark against it.

The competitive read: if you're running market access in obesity or cardiometabolic, your Medicare strategy just stopped being a rebate strategy and became a fulfillment strategy — and a competitor's turnaround time is now a number your leadership will ask you to match. The open thread is the expiry date. This runs to the end of 2027. Whoever owns the patient relationship the day it lapses is holding the asset.

And the company with the most at stake in that sentence reported twenty-four hours ago.

Staying with Lilly — Wednesday's print is the other half of this story. Second quarter earnings of eight dollars thirty-eight a share against consensus of six dollars and one cent. Sales, twenty-two point nine seven four billion against twenty point seven two five expected. Stock gained over five percent on the day. And the injectable GLP-1 franchise beat expectations again.

Which franchise beat is the part that matters. It's the injectable book — the same one that just got handed an automated Medicare on-ramp Lilly didn't build and doesn't control. They spent the quarter proving demand for products whose distribution they own slightly less of than they did last week. Meanwhile Foundayo, the pill sitting inside the bridge program, gets a national fulfillment ramp for free.

Free is doing a lot of work in that sentence.

It usually is. Ask again in eighteen months, when the channel has data on their patients that they don't.

Also worth noting on the deal side — AstraZeneca and Bristol Myers Squibb, which turns out to be no deal at all. The Financial Times reported merger talks Monday. AstraZeneca fell as much as nine point four percent intraday, seven percent on the Stockholm listing. Bristol Myers — market cap a hundred and thirty-three billion — went up six. Then Wednesday, a senior source told Reuters there is "no deal," and there "never was a deal to be done."

Look at the asymmetry, because that's the whole message. AstraZeneca shareholders were penalized for a mega-merger both parties say never existed. Bristol Myers shareholders were paid for the same non-event. Capital markets priced acquirer risk, not asset value — that's about as clean a reading of deal-skepticism as you'll ever get on a tape. Investor appetite has moved to targeted bolt-ons, and the instant a large industry combination is even rumored, AstraZeneca is the name that gets marked down for it.

Which is the practical takeaway if you're modeling consolidation into competitive scenarios. The binding constraint isn't strategic logic anymore. It's what your own shareholders will tolerate on the day it leaks.

On the regulatory front, the one worth real time is Insmed — and not for the reason the tape is celebrating. Second quarter, four hundred twenty-five point five million total. Brinsupri, three hundred nine point two million, forty-nine percent growth over the first quarter. Arikayce, a hundred sixteen point three million, up eight percent year over year. Full-year Brinsupri guidance raised to one point two five to one point four billion. Stock closed up thirty-three percent.

And they lifted peak revenue on the three lead programs to more than fourteen billion combined — better than seven billion for Brinsupri, six-plus for TPIP, north of one for Arikayce.

The regulatory calendar underneath those numbers is where all of that gets decided. A Japanese decision on brensocatib in non-cystic-fibrosis bronchiectasis is expected in the second half of this year. And in July they filed a supplemental NDA in the U.S. for Arikayce in newly diagnosed MAC lung disease — that's a move out of refractory patients and into the front line. If that label lands, the more-than-one-billion peak on Arikayce is conservative. If it doesn't, that number is the ceiling.

Label first, as always.

The item nobody put in a headline is the EMBARC collaboration from June — a three-year, open-label interventional study of twenty-five milligram brensocatib, built to evaluate disease modification in bronchiectasis. Three years is a very long time to fund a study you don't intend to take to a label. That isn't launch support. That's a company assembling evidence to change what the drug is permitted to claim. Watch it, because it's the difference between a well-launched respiratory product and a franchise that holds for a decade.

Looking ahead, the Insmed calendar is dense. Japan on brensocatib in the second half. The Arikayce supplemental under review. A Phase 3 in progressive pulmonary fibrosis guided to start this half, idiopathic pulmonary fibrosis in the first half of 2027. Their second DPP1 inhibitor, INS1033, cleared IND for rheumatoid arthritis in July, with Phase 1 in healthy volunteers this quarter. And on Amazon — same-day delivery reaches nearly four and a half thousand locations by year-end.

What I'm watching is narrower than any of that. Whether the sub-twenty-four-hour prior authorization number becomes the benchmark. Once one distributor publishes a turnaround time, every payer conversation in the category gets measured against it — and the access teams who can't answer the question will find out what it costs them. That stops being an obesity story fast. That's every specialty launch on the 2027 calendar.

The one I'll be sitting with tonight is that three-year EMBARC study. Committing to interventional data over that horizon in bronchiectasis is genuinely unusual, and I want to see the endpoints the day they publish. Have a good evening, everyone.

And that is your Pharma Closeout for Thursday, August 6th — Amazon at fifty dollars a month, Lilly's eight thirty-eight, Insmed up a third in a session, and a merger that never was and still cost somebody money. Follow the show on Spotify, Apple Podcasts, or wherever you listen — tomorrow's briefing lands on its own.